La Jolla Pharmaceutical Co. (NASDAQ:LJPC) shares moved down -4.64% in last trading session and ended the day at $25.30. LJPC has a return on assets of -66.80%. La Jolla Pharmaceutical Co. (NASDAQ:LJPC) quarterly performance is -16.91%.
La Jolla Pharmaceutical Company (NASDAQ:LJPC) had its target price upped by Chardan Capital from $60.00 to $80.00 in a research report sent to investors on Tuesday, Market Beat.com reports. They currently have a buy rating on the biopharmaceutical company’s stock.
Fossil Group, Inc. (NASDAQ:FOSL) ended the last trading day at $55.51. Company weekly volatility is calculated as 3.86% and price to cash ratio as 10.70. Fossil Group, Inc. (NASDAQ:FOSL) showed a weekly performance of -0.88%.
Jennifer Pritchard notified Fossil Group, Inc. (NASDAQ:FOSL) that, effective October 12, 2015, she resigned her position as President, Skagen to pursue other interests. Ms. Pritchard’s departure is not the result of any disagreement with the Company regarding its operations, policies or practices. Ms. Pritchard joined the Company in September 2006 and has served as President, Skagen since July 2013.
On 05 October, Lennar Corporation (NYSE:LEN) shares advanced 2.71% and was closed at $50.41. LEN EPS growth in last 5 year was 25.70%. Lennar Corporation (NYSE:LEN) year to date (YTD) performance is 12.78%.
On 21st September, Lennar Corporation (NYSE:LEN), reported results for its third quarter ended August 31, 2015. Third quarter net earnings attributable to Lennar in 2015 were $223.3 million, or $0.96 per diluted share, compared to third quarter net earnings attributable to Lennar in 2014 of $177.8 million, or $0.78 per diluted share.
Titan International Inc. (NYSE:TWI) shares advanced 10.17% in last trading session and ended the day at $7.26. TWI Gross Margin is 10.10% and its has a return on assets of -3.70%. Titan International Inc. (NYSE:TWI) quarterly performance is -27.20%.
The Board of Directors of Titan International, Inc. (NYSE:TWI) has approved a quarterly cash dividend of $.005 (one half cent) per common share for the third quarter of 2015. The cash dividend is payable Thursday, October 15, 2015, to stockholders of record on Wednesday, September 30, 2015.
NovoCure Ltd (NASDAQ:NVCR) caters to the Healthcare space. On the last day of trading company shares ended up at $18.69. NovoCure Ltd (NASDAQ:NVCR) distance from 50-day simple moving average (SMA50) is 2.24%.
Novocure announced that the U.S. Food and Drug Administration (FDA) has approved Optune in combination with temozolomide for the treatment of adult patients with newly diagnosed glioblastoma (GBM). Optune is a portable, non-invasive device that delivers low-intensity, intermediate frequency, alternating electric fields – referred to as Tumor Treating Fields (TTFields) – that inhibit cancer cell replication and cause cancer cell death.
Leave a Reply